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Abstract
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Repair of tooth supporting alveolar bone defects caused by
periodontal and peri-implant tissue destruction is a major goal
of reconstructive therapy. Oral and craniofacial tissue
engineering has been achieved with limited success by the
utilization of a variety of approaches such as cell-occlusive
barrier membranes, bone substitutes and autogenous block
grafting techniques. Signaling molecules such as growth
factors have been used to restore lost tooth support because of
damage by periodontal disease or trauma. This paper will
review emerging periodontal therapies in the areas of materials
science, growth factor biology and cell/gene therapy. Several
different polymer delivery systems that aid in the targeting of
proteins, genes and cells to periodontal and peri-implant
defects will be highlighted. Results from preclinical and clinical
trials will be reviewed using the topical application of bone
morphogenetic proteins (BMP-2 and BMP-7) and platelet-
derived growth factor-BB (PDGF) for periodontal and peri-
implant regeneration. The paper concludes with recent
research on the use of ex vivo and in vivo gene delivery
strategies via gene therapy vectors encoding growth
promoting and inhibiting molecules (PDGF, BMP, noggin and
others) to regenerate periodontal structures including bone,
periodontal ligament and cementum.
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Introduction
Tissue engineering, according to National Institute of
Health definition, is an emerging multidisciplinary field
involving biology, medicine, and engineering that is
likely to revolutionize the way we improve the health
and quality of life for millions of people worldwide by
restoring, maintaining, or enhancing tissue and organ
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function (1). For periodontal tissue engineering, this
specifically relates to repair of alveolar bone, tooth-
associated cementum and periodontal ligament (PDL)
(2).
Roughly, 20 000 organ transplants, 500 000 joint
replacements, and literally millions of dental–oral–
craniofacial procedures, ranging from tooth restora-
tions to major reconstruction of facial hard and soft
tissues are performed annually. According to the
National Institute of Dental and Craniofacial Research,
86% of adults over 70 years have at least moderate
periodontitis and over a quarter have lost their teeth,
which has serious repercussions on health and quality
of life (3).
To date, artificial replacements possess significant
limitations when compared with the natural original
tissues in terms of function and esthetics. Bridges and
dentures have been used for centuries in dentistry but
require periodic maintenance or even replacement
after a period of time because of usage or loss of
adaptation. The new generation of titanium dental
implants emerged as an innovative predictable treat-
ment for edentulism and support for prosthetic resto-
rations (4). Nevertheless, the procedure is technically
sensitive, costly and requires considerable recipient
bone quality and volume characteristics for acceptable
functional and esthetic outcomes.
The field of dental tissue engineering, once viewed
only as an experimental area of interest, is now
revealing early success for human application (5). In
this review article, we will highlight emerging concepts
and results of the application of biomaterials, growth
factors and cell/gene therapy in periodontology that
aid in the targeting of proteins, genes and cells to
bioengineer the periodontium.
The foundation of dental bioengineering has ancient
roots. Replacing body parts goes back at least
2500 years, when the Etruscans learned to substitute
missing teeth with bridges made from artificial teeth
carved from the bones of oxen (6). Evidence of crude
dental implants dates back to Roman populations of
the first or second century AD and to pre-Columbian
cultures of Central and South America (7). The first use
of dental amalgam to repair decayed teeth was recor-
ded in the Chinese literature in the year 659 (8).
Contemporary discoveries provide historic back-
ground for the advances of the bioengineering field
discussed in this paper. Urist hypothesized that a bone-
inducing substance, which he subsequently termed
bone morphogenetic protein’ (BMP), was responsible
for these observations (9). Melcher suggested that cells
that repopulate the periodontal wound would deter-
mine the type of new attachment onto the root surface.
Based on Melcher’s theory, physical barriers have been
used to retard apical migration of epithelial cells fav-
oring the healing by cells from the PDL region and
adjacent alveolar bone (10).
Achieving periodontal regeneration
The regeneration of the periodontal tissues is depend-
ent on four basic components. The appropriate signals,
cells, blood supply and scaffold need to target the tissue
defect (Fig. 1). Each of these elements plays a funda-
mental role on the healing process in a simultaneous
Fig. 1. Schematic representation of critical
elements required in periodontal tissue
engineering. Reconstruction of lost periodon-
tal tissue requires the combination of cells,
scaffolds, signaling molecules, and a blood
supply. A limiting factor in the achievement of
periodontal regeneration is the presence of
microbial pathogens that contaminate perio-
dontal wounds and reside on tooth surfaces as
plaque-associated biofilms.
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and temporal timeframe and is interconnected into the
generation of new tissues. Cells provide the machinery
for new tissue growth and differentiation. Growth fac-
tors or morphogens modulate the cellular activity and
provide stimuli to cells to differentiate and produce
matrix toward the developing tissue. New vascular
networks promoted by angiogenic signals provide the
nutritional base for tissue growth and homeostasis.
Finally, scaffolds guide and create a template structure
three-dimensionally to facilitate the above processes
critical for tissue regeneration. A major complication
and limiting factor in the achievement of periodontal
regeneration is the presence of microbial pathogens
that contaminate periodontal wounds and reside on
tooth surfaces as plaque-associated biofilms (11).
Appropriate strategies in controlling infection at the
reparative wound site are required to optimize perio-
dontal regeneration.
Cells contributing to periodontal repair
Specialized tissues such as the periodontium include
epithelial–mesenchymal interactions and junctional
complexes (to the tooth and connective tissues). The
native periodontium includes alveolar bone, cementum,
junctional epithelium and a gingival connective attach-
ment. Based on its embryonic origin, the periodontal
tissues form by the interaction of mesenchymal and
epithelium cells that respond differently to a variety of
stimuli (12).Moreover, the sequence of events necessary
for periodontal regeneration relies on the following
independent but linked processes: osteogenesis,
cementogenesis, and connective tissue formation.
Indeed, the harsh environment and the continual pres-
ence of pathogens and their by-products (notably endo-
toxin) contaminate the tooth root surfaces and wounds,
which are considered significant limiting factors for
achieving predictable periodontal regeneration (5,11).
The cellular constitution of the gingival connective
tissue and alveolar bone include: fibroblasts, macr-
ophages, mast cells, osteoblasts and osteoblast precur-
sor cells, cementoblasts and cementoblast precursor
cells, osteoclasts and odontoclasts, assorted inflamma-
tory cells, and cells that make up vascular channels and
nerves. Inflammatory cells include polymorphonuclear
leucocytes, lymphocytes, and plasma cells (13). The
connective tissue also contains undifferentiated
ectomesenchymal cells that serve as a replacement
source for more differentiated cells, primarily fibro-
blasts. Fibroblasts are irregularly shaped cells res-
ponsible for the maintenance and remodeling of
the connective tissue, synthesizing and removing
connective tissue fibers and the ground substance in
which they are embedded (14).
The PDL contains fibroblasts, macrophages, undif-
ferentiated ectomesenchymal cells, cementoblasts and
cementoclasts, osteoblasts and osteoclasts, cell rests of
Malassez and vascular and neural elements that are
capable of generating and maintaining three distinct
tissues, PDL, and the mineralized tissues: cementum
and alveolar bone (13,15). As specific cell lineages
retain the potential of regeneration (12,16), stimulatory
(9) and selective (10) approaches have been attempted
to re-engineer lost periodontal supporting tissues.
Guided tissue regeneration and cell
re-population
The biological principle of using cell-occlusive barriers
was described by Melcher on the repair potential of
periodontal tissues (10). It was demonstrated that gui-
ded tissue regeneration (GTR) could be driven by
excluding or restricting the re-population of perio-
dontal defects by epithelial and gingival connective
cells. Thus, providing space and favorable niche to
maximize PDL cells, cementoblasts, and osteoblasts to
migrate selectively, proliferate and differentiate within
the periodontal defects help in promoting the recon-
struction of the supporting tissue and attachment (17).
Cellulose membranes were the first biomaterial
applied as surgical barriers for periodontal GTR, fol-
lowed by expanded polytetrafluoroethylene (ePTFE)
(18) and a variety of absorbable polymers (19). Current
used materials include polylactic acid, polyglycolic
acid, polyglactin, and both soluble and non-soluble
collagen barriers (20). A list of cell-occlusive devices
including non-absorbable and absorbable barriers is
shown in Table 1. The use of non-absorbable barriers
requires a second surgical procedure for barrier
removal, usually performed after 4–12 weeks following
surgery. Absorbable barriers made from synthetic
polymers are biocompatible, and biodegradable
through physicochemical hydrolysis. Collagen barriers,
made of type I collagen from bovine or porcine tissues,
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are degraded through enzymatic processes that may
take from 6–8 weeks to as long as 4–8 months. In
comparison with non-absorbable barriers, the absorb-
able types exhibit the advantage of easy adaptation to
the defect area without need for barrier removal (21).
More recently, Lee et al. have shown that ceramic
barriers impregnated with BMP-2 greatly improved
craniofacial bone regeneration in vivo (22). This new
approach of combining (selective and stimulatory)
physical barriers with bioactive molecules offers tre-
mendous possibilities for bone tissue engineering (23).
Cell therapy
To date, cell therapy aimed to engineer tissues has just
recently been employed to periodontology (Fig. 2). A
human oral mucosa equivalent was successfully
assembled ex vivo by Izumi et al. (24). The engineered
mucosa, consisting of epidermal and dermal compo-
nents, in a defined essential-fatty-acid-deficient serum-
free culture medium without a feeder layer, can
potentially be used for intra-oral grafting in humans
(24). The use of cell expansion in an ex vivo environ-
ment for subsequent transplantation provides extra
material in cases of insufficient donor tissue.
Somerman et al. have also demonstrated the poten-
tial use of cell therapy with cloned cementoblasts (25).
In a series of reports, the group has cloned and char-
acterized a cementoblast cell line, which possesses
many of the phenotypic characteristics of tooth-lining
cells in vivo. More recently, it has been demonstrated
that transplantation of cloned cementoblasts into poly-
lactide-co-glycolide acid (PLGA) carriers leads to the
repair of large periodontal alveolar bone defects in
rodents (26). The achieved regenerationwas only limited
by the sizeof the transplantedPLGAcarrier. Jin et al. have
also shown that skin fibroblasts transduced by the
BMP-7 gene promoted the tissue engineering of perio-
dontal bone defects including new bone, functional
PDL and tooth root cementum (27). By utilizing stra-
tegies to better understand the basic biologic mecha-
nisms involved in cementogenesis, optimal therapies for
periodontal wound healing may be developed.
Growth factors for periodontal
regeneration
In order to enhance the in vivo efficacy, incorporation
of bioactive molecules into scaffolding materials may
Table 1. Cell-occlusive barriers used for periodontal regeneration
Cell-occlusive barrier Trade name
Non-resorbable
Cellulose, ePTFE Millipore filter,
Gore-Tex
Resorbable





Bovine tendon type I,








Fig. 2. Cell therapy for periodontal tissue engineering: (A) SEM image
of poly-lactide-co-glycolide acid (PLGA) scaffold and seeded cells into
scaffolds; (B) tissue engineering approach for ectopic mineralization
in mice, cells are expanded in culture prior to being seeded into the
scaffolds for implantation; (C) periodontal ligament cells (PDL) do
not promote mineralization in vivo, while cementoblasts show min-
eralization, 20· magnification.
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facilitate sustained factor release for periods of time.
There are two basic modes of incorporating bioactive
molecules into the scaffolds at the time of fabrication
(28) or after the fabrication (29). Bioactive molecules
incorporated directly into a bioresorbable scaffold are
generally released by a diffusion-controlled mechanism
that is regulated by the pore sizes such that different
pore sizes affect the tortuosity of the scaffold and
thereby control the release of protein (30). The rate
of growth factor release depends on the type and rate of
degradation of the delivery device, and the rate of
growth factor diffusion through pores of the scaffolds.
Wei et al. has incorporated human parathyroid hor-
mone (PTH) into biodegradable PLGA microspheres
and demonstrated that PTH could be released in a
controlled fashion (31). These polymer microspheres
were able to preserve the bioactivity of the PTH as
evidenced by the stimulated release of cAMP by rat
osteosarcoma cells in vitro as well as increased serum
calcium levels when injected subcutaneously into mice.
Murphy et al. have shown the release of vascular
endothelial growth factor (VEGF, a potent mitogen
specific for endothelial cells) from PLGA scaffolds for
up to 15 days (32). Moreover, enhanced vascularization
in the scaffold has been observed when the VEGF-
incorporated polymers seeded with endothelial cells
were implanted in vivo (33). In addition, it has been
shown that insulin-like growth factor (IGF)-1/trans-
forming growth factor (TGF)-1 incorporated in PLGA
microspheres is gradually released over 15 days (34).
The in vitro culture of IGF-1/TGF-1 containing micro-
spheres photoencapsulated with chondrocytes in a
hydrogel system resulted in increased cell numbers and
glycosaminoglycan production compared with the
control gels either with or without microspheres at
2 weeks (34). Recently, Lutolf et al. showed that
hydrogels that contain cell adhesive molecule motif
RGD (arginine-glycine-aspartic acid) and substrates for
matrix metalloproteinases as linkers to polymer chains
work as biomimetic scaffolds (35). This approach works
efficiently as cell invasion into the scaffolds regulates
the release of BMPs to heal craniofacial defects.
Development of suitable controlled-release of the bio-
active molecules devices and/or alternative mode of
delivery is needed.
Several bioactive molecules have demonstrated
strong effects in promoting periodontal wound repair in
preclinical and clinical studies. These bioactive mole-
cules include PDGF (36), IGF-I (37), basic fibroblast
growth factor (FGF-2) (38), TGF-1 (39), BMP-2 (40), -4
(41), -7 (42) and -12 (43), and enamel matrix derivative
(EMD) (44) that have shown positive results in stimu-
lating periodontal regeneration. In addition, PDGF,
BMP-2, and BMP-7 have been shown to promote peri-
implant bone regeneration (2). Recently, a comparative
study in periodontal defects found that rhBMP-2 in
association with collagen sponges promoted superior
bone regeneration than rhBMP-12. Cementum forma-
tion is similar for both BMPs, however, only the rhBMP-
12 treatment induces to functionally oriented PDL
bridging newly formed bone and new cementum (43).
The details of preclinical and clinical studies have
been reviewed in several articles (2,5,12,45–47). In
general, the results from the in vivo studies have shown
that all of the above-mentioned bioactive molecules,
with the exception of TGF-1, exhibited an ability to
promote periodontal tissue regeneration. BMPs
showed the greatest potential in critical-size defects, as
they are potent osteoinductive mediators. A phase I/II
human trial using a combination of PDGF and IGF-I
demonstrated the stimulation of alveolar bone repair in
patients with severe periodontal disease (48). Table 2
presents a list of growth factors and their effects on
PDL cells, cementoblasts and osteoblasts. Future ther-
apy using various combinations of growth factors
promoting optimal periodontal tissue regeneration
warrant further investigation.
Scaffold and extracellular matrix
The extracellular matrix is a biologically active tissue
composed of a complex mixture of macromolecules,
that in addition to serving a structural function, also
profoundly affect the cellular physiology of an organ-
ism (47). Cell adhesion, migration, proliferation and
differentiation are examples of biological processes
influenced by the composition and structural organ-
ization of surrounding extracellular matrices (49).
Studies have shown the critical role of the extracel-
lular matrix substrata in bone induction by BMPs,
particularly in craniofacial morphogenesis and regen-
eration, which is contact-mediated (50). For example,
the rhBMPs delivered on wounds bind to heparan
sulfate, heparin, type II procollagen, fibrillins, prote-
oglycans, noggin, chordin, DAN, and types I and IV
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collagen of the extracellular matrix. Thus, extracellular
matrix components combine active morphogens to
confer the optimal conformation, which then can ini-
tiate contact-mediated interactions (51).
Considering that scaffolds simulate the extracellular
matrix, the rate of material degradation plays a critical
role on the initiation of tissue replacement for engin-
eered structures. A list of commercially available
biomaterials for tissue repair applications is shown in
Table 3. It was demonstrated by Lu et al. that the release
rate of growth factor from the scaffold can profoundly
affect the results (52). Furthermore, the pharmaco-
kinetics of the BMPs incorporated on biomaterials, such
as collagen and hydroxyapatite (53), may be different
from the kinetics in the bone, periodontium and teeth
because the retention of BMPs at the site of implanta-
tion is dependent on the charge characteristics and
isoelectric point of the morphogens (54).
Table 2. Effect of growth factors on periodontal ligament (PDL) cells, cementoblasts (CM) and osteoblasts (OB)
Growth factor effects Migration Proliferation Differentiation Matrix gene expression
Cell types PDL CM OB PDL CM OB PDL CM OB PDL CM OB
PDGF ++ ? ++ +++ +++ +++ ) ) ) ++ +/) +
IGF-1 ++ ? ++ + ++ + ) ? + + +/) ++
FGF-2 +++ ? +/) +++ ? +++ ) ? ) +/) ? +/)
TGF-b + ? ++ ++ ++ ++/) + ) +/) ++ +/) ++
BMPs ? ? ++ 0 ) + ) + +++ ? ++ ++
EMD ++ ? ++ ++ ++ ++ + +/) + + ++/) ++/)
()) Inhibition; (0) no effect; (+) effect; (?) unknown effect; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor; FGF, fibroblast growth
factor; TGF, transforming growth factor; BMP, bone morphogenetic protein; EMD, enamel matrix derivative.








Bovine mineral matrix, bovine-derived
hydroxyapaptite (HA)
Bio-Oss, OsteoGraf, Pep-Gen P-15
Alloplasts
Hydroxyapaptite





Hard-tissue replacement polymers Bioplant
Bioactive glass (SiO2, CaO, Na2O, P2O5) PerioGlas
, BioGran
Coral-derived calcium carbonate Biocoral
Polymers and collagens
Collagen Helistat, Collacote, Colla-Tec, Gelfoam
Poly(lactide-co-polyglycolide)
Methylcellulose
Hyaluronic acid ester Hy
Chitosan
Enamel matrix derivative Emdogain
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Angiogenic factors for periodontal repair
The periodontium is a highly vascularized tissue. Three
major sources of blood supply comes from 1) supra-
periosteal arterioles along the surface of alveolar bone,
2) vessels of the PDL region, and 3) arterioles from the
interdental septum extending into the gingival and
sulcus area (55). It is not only important to maintain
the local homeostasis and adequate host defense by
transporting cells and defensins to the gingival crevice
(56), the blood supply has a key role on the nutrition of
newly engineered tissues. However, a major challenge
in periodontal regeneration is the targeting of angio-
genesis to an avascular tooth root surface.
Subsequent to an injury, capillaries invading a fibrin
clot will deliver nutrients, inflammatory cells, and
oxygen to the wound site for early granulation tissue
formation (57). Additionally, new blood vessels will
contribute to provide an adequate environment for cell
migration, proliferation, differentiation and extracellu-
lar matrix synthesis; all essential features noted during
the initial phases of periodontal healing (58).
Basic fibroblast growth factor (bFGF or FGF-2) has
been demonstrated to have potent angiogenic activity
(59) and potential to induce the growth of immature
PDL cells (38). The mRNA level of laminin in PDL cells,
which plays an important role in angiogenesis, is
upregulated by FGF-2 stimulation (38). Also, a recent
report addressed the effect of the EMD on the stimu-
lation of angiogenesis of the periodontal wounds (60).
These factors may in turn accelerate periodontal
regeneration.
Although EMD has angiogenic effects both in vitro
and in vivo (60), the more rapid initial healing may not
be directly influenced by the angiogenic effect of EMD
alone. At least two other mechanisms probably con-
tribute to the acceleration of wound healing. First, PDL
cells can secrete growth factors, including TGF-b1, IL-6,
and PDGF-AB after exposure to EMD (44,61). TGF-b1
and PDGF-AB have been shown to accelerate the rate
of healing in periodontal wounds by specifically sti-
mulating the proliferation of PDL cells (12,37,62,63).
Second, it has been demonstrated that EMD can
modulate the bacterial growth of putative periodon-
tal pathogens (Actinobacillus actinomycetemcomitans,
Porphyromonas gingivalis, and Prevotella intermedia),
but not the normal flora during periodontal wound
healing (60,64).
The technical challenges confronting the tissue
engineering of vasculature are many (65). First is the
selection of appropriate vascular cells and scaffold
materials. The majority of studies to date typically
involve in vitro culturing of bone marrow cells or
smooth muscle cells in combination with a collagen-
based matrix until a tubular structure is formed, sub-
sequently allowing endothelial cells to attach to the
vessel wall (66). Scaffolds need to be designed to
support the proper formation of vascular tissue and
possess the mechanical properties that can match
those of native arteries. The synthetic vessel must
withstand the fluid shear stress and strain from
blood flow and have an adequate burst strength to
withstand physiological blood pressures (65). Finally,
incompatibilities between synthetic engineered grafts
and native blood vessels must be quantified and
evaluated.
Growth factors are often required to promote tissue
regeneration, as they can induce angiogenesis, which
supplies oxygen and nutrients to cells in order to
maintain their biological functions. However, the bio-
logical effects of growth factors cannot always be
expected because of their poor in vivo stability, unless a
drug delivery system is contrived. Present and future
studies involving the incorporation of angiogenic
growth factors (most notably VEGF) directly into scaf-
folds (67), or using gene therapy to deliver growth
factors to these sites may prove to be an important key
for stimulating new vessel formation (68). In a dual
growth factor delivery model targeting rapid formation
of mature vascular networks, it was demonstrated that
both PDGF + VEGF, each with distinct kinetics,
improve angiogenesis by leading the formation of a
significant number of blood vessels and inducing their
maturation (69).
Gene therapy for periodontal engineering
As the half-life of growth factors in vivo is transient (on
the order of minutes to hours), periodontal regener-
ation is not a common outcome following conventional
surgical therapy. Typically, high concentrations of
growth factors are required to promote tissue regen-
eration (70). Therefore, supplemental local growth
factor production via gene transfer could be superior to
bolus delivery methods.
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Simply stated, gene therapy consists of the insertion
of genes into an individual’s cells either directly or
indirectly with a matrix to promote a specific biological
effect. Gene therapy typically aims to supplement a
defective mutant allele with a functional one in a
therapeutic approach but can also be used to induce
Day 10 Day 21 High power
Fig. 3. Bone regeneration via cartilage intermediate: recombinant adenovirus encoding murine BMP-7 (Ad-BMP-7) promoting periodontal
bone regeneration via a cartilage intermediate evaluated after 10 and 21 days of ex vivo gene transfer to periodontal wounds. After 10 days,
specimens demonstrated islands of cartilage and chondroblast-like cells. After 21 days, specimens demonstrated woven bone and mature
cartilage intimately associated with newly formed bone. The bottom panel shows an image of chondroblast-like cells and cartilaginous matrix
surrounded by new bone adjacent to the tooth surface. H&E and toluidine blue staining at 10· magnification, high power image at 20·
magnification. Reprinted in part from Jin et al. (27), with permission.
Fig. 4. Gene delivery strategies for tissue engineering: ex vivo approach, tissue biopsy from donor site have cells isolated and expanded in cell
culture. Vectors (e.g. adenovirus or plasmids) are used to transduce the cells in vitro. Cells are then seeded onto biodegradable scaffolds
delivered to the wound site. In the in vivo approach, genes are directly delivered to the wounds using (in this example) collagen gel as a carrier.
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a more favorable host response. Targeting cells for gene
therapy requires the use of vectors or direct delivery
methods to transfect them.
Using an ex vivo approach for periodontal repair, Jin
et al. used BMP-7 gene transfer to stimulate new
alveolar bone, tooth root cementum, and PDL (27).
Ad-BMP-7 or its antagonist, Ad-noggin transduced
syngeneic dermal fibroblast that were seeded onto
gelatin carriers and transplanted into large alveolar
bone defects. The repair of periodontal defects was
observed through a rapid chondrogenesis, followed by
osteogenesis, cementogenesis and predictable bridging
of the bone defect (Fig. 3) (27). Noggin gene transfer on
the other hand blocked periodontal bone and cemen-
tum repair both in periodontal defects (27) and in tis-
sue-engineered cementum (42).
PDGF has demonstrated strong potential in promo-
ting gingival (71), alveolar bone (72), and cementum
(73) regeneration in a variety of wound healing models
(Fig. 4) (72). When periodontal defects were treated
with adenovirus encoding PDGF-B, strong evidence of
bone and cementum regeneration beyond that of
control vectors, consisting of nearly fourfold increases
in bridging bone and sixfold increases in tooth-lining
cemental repair was seen (72). In addition, it was
demonstrated that a sustained and localized expression
of the luciferase reporter gene was ascertained at the
periodontal lesions for up to 21 days after gene transfer
(72).
Future perspectives
Many advances have been made over the past decade
in the reconstruction of complex periodontal and
alveolar bone wounds. Developments in polymeric and
ceramic scaffolding systems for cell, protein and gene
delivery have undergone significant growth. The tar-
geting of signaling molecules or growth factors (via
proteins or genes) to the periodontium has lead to
significant new knowledge generation using bioactive
molecules that promote cell proliferation, differenti-
ation, matrix biosynthesis, and angiogenesis. A major
challenge that has been overlooked has been the
modulation of the exuberant host response to micro-
bial contamination that plagues the periodontal wound
environment. For improvements in the outcomes in
periodontal regenerative medicine, scientists will need
to examine dual delivery of host modifiers or anti-
infective agents to optimize the results of therapy.
Further advancements in the field will continue to rely
heavily on multidisciplinary approaches combining
engineering, dentistry, medicine, and infectious disease
specialists in repairing the complex periodontal wound
environment.
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